Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05188339
Other study ID # IRB No.: 202100060A3
Secondary ID
Status Enrolling by invitation
Phase Phase 2/Phase 3
First received
Last updated
Start date July 20, 2022
Est. completion date December 31, 2022

Study information

Verified date April 2022
Source Chang Gung Memorial Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Studies that used a dilute citrate formulation (4%) demonstrated efficacy as an anticoagulant with minimal to no risk of bleeding in HD sessions. This study will compare effectiveness and safety utilizing 4% sodium citrate vs. heparin as a lock solution in central venous hemodialysis catheter among hemodialysis patients.


Description:

Vascular access is necessary for hemodialysis(HD) procedure. In normal situation, vascular access for HD is created in peripheral vessels. However, vascular catheter may be considered in patients without available peripheral vessels for vascular access. The characteristic of these patients include elderly, diabetes, not tolerant to vascular surgery etc.. Commonly, the HD catheter is inserted in the central vein in these population. Considering clotting condition, anticoagulant is indicated for catheter locking after HD session. In the past years, heparin is the most common solution to be used as locking solution. Nevertheless, heparin has a few disadvantages, such as systemic anticoagulation, thrombocytopenia, and bleeding risk. An alternative for anticoagulation in HD session is 4% sodium citrate. The effectiveness and safety of sodium citrate in HD sessions have been reported in clinical studies. Characteristics of sodium citrate and safety profile Trisodium citrate acts locally as an anticoagulant by chelating ionized calcium in blood, resulting in the blockage of calcium-dependent clotting pathways. Studies that used a dilute citrate formulation (4%) demonstrated efficacy as an anticoagulant with minimal to no risk of bleeding in HD sessions. The advantageous effects of sodium citrate in HD catheter locking solution includes reducing frequency of catheter exchanges, reducing using of thrombolytic drugs, reducing hospitalization rates, and bacteremia. Regarding adverse effect of sodium citrate, hypocalcemia and other untoward outcomes are rare reported in the previous clinical studies


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 120
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. Age >=20 years 2. End-stage renal disease patients who received regular HD weekly via central venous catheter for at least 3 months in outpatient clinic in Kaohsiung Chang Gung Memorial Hospital, Taiwan Exclusion Criteria: 1. bleeding tendency 2. on radiotherapy or chemotherapy for malignancy 3. pregnancy 4. drug allergy history to citrate 5. undefined reasons for refuted participation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
4% sodium citrate
Dose of 4% sodium citrate is also according to catheter lumen (LVR) instilled into each lumen of catheter after HD session, eg. 1.6 cc/lumen for LV R 1.6, 1.8 cc/lumen for LVR 1.8. A prospective, open label, control study. The content of study protocol will be posted in the HD room in the Kaohsiung Chang Gung memorial Hospital, Taiwan. After inform consent obtained, we will categorize enrolled participants randomly into two groups, 4% sodium citrate group(experimental group), heparin group(control group), respectively. The study duration is three months.
heparin group
Heparin dosage is based on volume ratio in catheter lumen (LVR) after each HD session, eg. 8000u/lumen in 1.6 LVR, 9000u/lumen in LVR 1.8.

Locations

Country Name City State
Taiwan Chang Gung Memorial Hospital Kaohsiung

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary central venous catheter exchanges We will record the episode of central venous catheter malfunction and central venous catheter exchanges within the period of trial and compare the incidence between two arms. 3 months
Secondary events of thrombolytic drug use, bacteremia and all-cause hospitalization days. We will record the episode of central venous catheter malfunction and events of thrombolytic drug use within the period of trial and compare the incidence between two arms.
We will also compare the incidence of bacteremia and all-cause hospitalization days within these 3 months.
3 months
See also
  Status Clinical Trial Phase
Completed NCT05189795 - The Construction of Physical ACtivity Enhancement Scheme (PACES) in Hemodialysis Patients
Completed NCT01125202 - Intervention to Reduce Dietary Sodium in Hemodialysis N/A
Completed NCT00730145 - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis Phase 1
Completed NCT00753116 - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension Phase 1
Completed NCT00806130 - Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients
Completed NCT05718765 - The Effect of Physical ACtivity Enhancement Scheme (PACES) in Hemodialysis Patients N/A
Completed NCT03250715 - Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure N/A
Completed NCT05469620 - Adaptive Nutrition Therapy in Hemodialysis N/A
Completed NCT03536858 - Social Networks and Renal Education: Promoting Transplantation N/A
Completed NCT00824837 - Study of beta2-Microglobulin Removal by Standard Versus New High Cut-Off Haemodialysis Membrane Phase 1/Phase 2
Completed NCT03403491 - Study of Self-monitoring of Weight & Blood Pressure (Via patientMpower Platform) in Hemodialysis N/A
Terminated NCT02495662 - The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation Phase 2
Completed NCT01179620 - Certoparin in Renal Patients Undergoing Hemodialysis Phase 3
Completed NCT01017276 - A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis Phase 3
Active, not recruiting NCT04466865 - A Communication Tool to Assist Older Adults Facing Dialysis Choices N/A
Recruiting NCT03782519 - Quality of Life of Frail Aged Patients in Incremental Hemodialysis N/A
Recruiting NCT02843334 - Study of the Prevalence of Fabry Disease in French Dialysis Patients N/A
Recruiting NCT02545530 - Transdermal Clonidine in Chronic Hemodialysis Patients N/A
Completed NCT00892749 - Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis Phase 3
Completed NCT00649298 - A Clinical Trial of IntensiVE Dialysis Phase 4